trending Market Intelligence /marketintelligence/en/news-insights/trending/tduZq9I7AHzdehdPpv87Kg2 content esgSubNav
In This List

Basilea drug receives US FDA qualified infectious disease product designation

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Basilea drug receives US FDA qualified infectious disease product designation

Basilea Pharmaceutica AG said the U.S. Food and Drug Administration granted qualified infectious disease product designation to its investigational drug ceftobiprole.

The cephalosporin antibiotic is intended to combat staphylococcus aureus bacteria, the leading cause of bloodstream infections.

The designation provides certain incentives for the development of antibiotics, such as priority review and a five-year market exclusivity extension should ceftobiprole be approved.

Basilea said it is preparing two phase 3 trials of the drug to support potential future registration in the U.S.